2005
DOI: 10.1007/s00280-005-1011-6
|View full text |Cite
|
Sign up to set email alerts
|

Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis

Abstract: Adjuvant treatment with capecitabine or 5-FU/LV in a small sample of patients with Dukes' C colon cancer was associated with alterations in hemolytic parameters. These alterations, in particular hyperbilirubinemia, were associated in some patients with low-grade compensated hemolytic anemia. All changes were clinically insignificant, fully reversible, and may represent a fluoropyrimidine class effect. Further studies are indicated to evaluate the incidence and implications of this effect.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2008
2008
2021
2021

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(1 citation statement)
references
References 24 publications
0
1
0
Order By: Relevance
“…Capecitabine is preferentially converted by tumour-selective mechanism via three step enzymatic cascade with higher concentrations of 5-FU in malignant cells as compared with normal tissues [5,6]. Although Capecitabine has greater therapeutic efficacy but the drug has proved to cause life threating toxicities which comprises of neurotoxicity [7], cardiotoxicity [8], gastrointestinal toxicity, dermotological toxicity, hematological imbalance [9] and also other manifestations include dermatological hand and foot syndrome [10], diarrhea and hepatic hyperbilirubinemia [11]. Therefore, due to its severe toxicity, determination of its accurate concentration in pharmaceutical dosages and biological fluids is very much essential and thus gained greater significance in drug quality control.…”
Section: Introductionmentioning
confidence: 99%
“…Capecitabine is preferentially converted by tumour-selective mechanism via three step enzymatic cascade with higher concentrations of 5-FU in malignant cells as compared with normal tissues [5,6]. Although Capecitabine has greater therapeutic efficacy but the drug has proved to cause life threating toxicities which comprises of neurotoxicity [7], cardiotoxicity [8], gastrointestinal toxicity, dermotological toxicity, hematological imbalance [9] and also other manifestations include dermatological hand and foot syndrome [10], diarrhea and hepatic hyperbilirubinemia [11]. Therefore, due to its severe toxicity, determination of its accurate concentration in pharmaceutical dosages and biological fluids is very much essential and thus gained greater significance in drug quality control.…”
Section: Introductionmentioning
confidence: 99%